Overview A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer Status: Completed Trial end date: 2021-04-12 Target enrollment: Participant gender: Summary The purpose of this study is to evaluate the efficacy of the study drug known as ramucirumab in participants with gastric and gastroesophageal cancer. Phase: Phase 3 Details Lead Sponsor: Eli Lilly and CompanyTreatments: Albumin-Bound PaclitaxelPaclitaxelRamucirumab